MUM1 inhibitors represent a specific class of chemical compounds designed to interfere with the activity of the MUM1 (Multiple Myeloma 1) protein, which is a transcription factor involved in various biological processes, including the regulation of gene expression. As a member of the interferon regulatory factor (IRF) family, MUM1 plays a crucial role in modulating immune response, cellular differentiation, and proliferation. The inhibition of MUM1 can have far-reaching consequences in molecular biology, especially in the study of transcriptional regulation mechanisms. By selectively targeting MUM1, researchers can dissect its involvement in specific signaling pathways and its downstream effects on the expression of certain genes. These inhibitors are valuable tools in cellular biology, enabling the exploration of MUM1's influence on chromatin remodeling and epigenetic modifications.
From a chemical perspective, MUM1 inhibitors are often small molecules engineered to achieve high specificity for the MUM1 protein. Their design typically revolves around a core structure capable of binding to the MUM1 transcription factor, thus preventing its interaction with DNA or other co-factors that facilitate transcriptional activity. These inhibitors may feature diverse functional groups and moieties that confer the necessary affinity and selectivity for MUM1 binding. In the development and refinement of these compounds, various chemical techniques, including structure-activity relationship (SAR) studies, are employed to optimize potency and selectivity. MUM1 inhibitors are synthesized and analyzed using advanced spectroscopic, crystallographic, and chromatographic techniques, allowing researchers to precisely characterize their molecular interactions and binding properties. This class of inhibitors, by providing insight into the fundamental molecular interactions within transcriptional networks, has emerged as a key focus in the study of gene regulation and molecular biology.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
May modulate the activity of immune cells, indirectly affecting MUM1 expression in hematological malignancies. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Could affect cytokine production and immune responses, indirectly modulating MUM1 expression. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
BTK inhibitor that may impact B-cell receptor signaling, potentially influencing MUM1 expression. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK inhibitor; may modulate cytokine signaling pathways affecting MUM1 expression. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
PI3Kδ inhibitor; could influence B-cell activation and survival, possibly affecting MUM1 expression. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor; may indirectly influence MUM1 expression through apoptosis regulation in malignancies. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Tyrosine kinase inhibitor that might affect various signaling pathways influencing MUM1 expression. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
BTK inhibitor; may impact B-cell receptor signaling, potentially affecting MUM1 expression. | ||||||
IPI 145 | 1201438-56-3 | sc-488318 | 5 mg | $317.00 | ||
PI3K inhibitor; could modulate cell survival and activation pathways, influencing MUM1 expression. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
JAK inhibitor; could influence cytokine-mediated signaling pathways, affecting MUM1 expression. | ||||||